トログリタゾン (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "トログリタゾン" in Japanese language version.

refsWebsite

Global rank Japanese rank

6nih.gov

4^th place

24^th place

5doi.org

2^nd place

6^th place

3nytimes.com

7^th place

63^rd place

2u-tokyo.ac.jp

1,856^th place

142^nd place

2pulitzer.org

2,337^th place

7,350^th place

2fda.gov

447^th place

1,043^rd place

1mhlw.go.jp

1,656^th place

110^th place

1pmrj.jp

low place

1wired.com

193^rd place

739^th place

1nikkeibp.co.jp

1,415^th place

95^th place

1yakugai.gr.jp

low place

1hateblo.jp

low place

4,591^st place

1icis.com

low place

1bbc.co.uk

8^th place

73^rd place

1pmda.go.jp

6,690^th place

394^th place

1diabetesjournals.org

low place

1nejm.org

2,374^th place

2,486^th place

1npojip.org

low place

1lifescience.co.jp

low place

1kanbyotaiseiri.com

low place

bbc.co.uk

news.bbc.co.uk

British Broadcasting Corporation (1 December 1997). “Diabetes drug withdrawn from sale”. BBC 12 December 2012閲覧。

diabetesjournals.org

intl-care.diabetesjournals.org

Diabetes Prevention Research Group (April 1999). “Design and methods for a clinical trial in the prevention of type 2 diabetes”. Diabetes Care 22 (4): 623–634. doi:10.2337/diacare.22.4.623 12 December 2012閲覧。.

doi.org

Cohen, J. S. (2006). “Risks of troglitazone apparent before approval in USA”. Diabetologia 49 (6): 1454–5. doi:10.1007/s00125-006-0245-0. PMID 16601971.
Aljada A, Garg R, Ghanim H, et al. (2001). “Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?”. J. Clin. Endocrinol. Metab. 86 (7): 3250–6. doi:10.1210/jc.86.7.3250. PMID 11443197.
Keen H (November 1994). “Insulin resistance and the prevention of diabetes mellitus”. N. Engl. J. Med. 331 (18): 1226–7. doi:10.1056/NEJM199411033311812. PMID 7935664.
Diabetes Prevention Research Group (April 1999). “Design and methods for a clinical trial in the prevention of type 2 diabetes”. Diabetes Care 22 (4): 623–634. doi:10.2337/diacare.22.4.623 12 December 2012閲覧。.
Diabetes Prevention Program Research Group (7 February 2002). “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin”. The New England Journal of Medicine 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527 12 December 2012閲覧。.

fda.gov

accessdata.fda.gov

“www.accessdata.fda.gov”. 2014年11月5日閲覧。

fda.gov

U.S. Food and Drug Administration. “2000 Safety Alerts for Human Medical Products”. U.S. Food and Drug Administration. 12 December 2012閲覧。

hateblo.jp

honyakukaisya.hateblo.jp

“大型化が期待される糖尿病治療薬「ノスカール」” (2014年5月15日). 2014年11月5日閲覧。

icis.com

Sinclair, Neil (31 July 1997). “Glaxo Wellcome gets approval for Romozin”. ICIS News 12 December 2012閲覧。

kanbyotaiseiri.com

“薬物誘起性肝障害の発現とグルタチオン-S- 転移酵素の遺伝子型との関係に関する検討”. 2014年11月5日閲覧。

lifescience.co.jp

“肝障害の原因は反応性代謝物トログリタゾンとアセトアミノフェン”. 2014年11月5日閲覧。

mhlw.go.jp

“糖尿病治療薬トログリタゾン投与に伴う重篤な肝障害に関する緊急安全性情報の配布について” (1997年12月1日). 2014年11月5日閲覧。

nejm.org

Diabetes Prevention Program Research Group (7 February 2002). “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin”. The New England Journal of Medicine 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527 12 December 2012閲覧。.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohen, J. S. (2006). “Risks of troglitazone apparent before approval in USA”. Diabetologia 49 (6): 1454–5. doi:10.1007/s00125-006-0245-0. PMID 16601971.
Aljada A, Garg R, Ghanim H, et al. (2001). “Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?”. J. Clin. Endocrinol. Metab. 86 (7): 3250–6. doi:10.1210/jc.86.7.3250. PMID 11443197.
Henry RR (September 1996). “Effects of troglitazone on insulin sensitivity”. Diabet. Med. 13 (9 Suppl 6): S148–50. PMID 8894499.
Keen H (November 1994). “Insulin resistance and the prevention of diabetes mellitus”. N. Engl. J. Med. 331 (18): 1226–7. doi:10.1056/NEJM199411033311812. PMID 7935664.
Diabetes Prevention Program Research Group (7 February 2002). “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin”. The New England Journal of Medicine 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926. PMID 11832527 12 December 2012閲覧。.